Covered recipient · General Payments record
NEIL LIN KAO
Allopathic & Osteopathic Physicians Allergy & Immunology Allergy
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$2,257.33
114 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,257.33 | 114 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $482.96 | 19 |
| PFIZER INC. | $263.51 | 15 |
| GENZYME CORPORATION | $242.84 | 17 |
| Regeneron Healthcare Solutions, Inc. | $181.13 | 4 |
| GlaxoSmithKline, LLC. | $177.45 | 17 |
| Optinose US, Inc. | $155.83 | 4 |
| Covis Pharma GmBH | $146.02 | 10 |
| Takeda Pharmaceuticals U.S.A., Inc. | $133.58 | 6 |
| Genentech USA, Inc. | $131.98 | 7 |
| CSL Behring | $88.66 | 4 |
| ALK-Abello, Inc | $73.82 | 1 |
| AIMMUNE THERAPEUTICS, INC. | $24.02 | 1 |
| Eyevance Pharmaceuticals LLC | $23.69 | 1 |
| kaleo, Inc. | $22.06 | 1 |
| HOSPIRA, INC. | $20.19 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.79 | 1 |
| Merck Sharp & Dohme Corporation | $17.61 | 1 |
| Octapharma USA, Inc. | $14.76 | 1 |
| Grifols USA, LLC | $14.59 | 1 |
| Teva Pharmaceuticals USA, Inc. | $12.17 | 1 |
| Bio Products Laboratory USA, Inc. | $11.67 | 1 |
Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NEIL LIN KAO
NPI 1720089477 · CMS profile ID 32539
Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy
GREENVILLE, SC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1720089477?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NEIL LIN KAO, NPI 1720089477, CMS profile ID 32539. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720089477?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). NEIL LIN KAO, NPI 1720089477, CMS profile ID 32539. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720089477?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- NEIL LIN KAO, NPI 1720089477, CMS profile ID 32539, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1720089477?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
114 matching records · $2,257.33 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–114 of 114.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $19.79 | 02/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832666053 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.51 | 02/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834344331 | CMS |
| GlaxoSmithKline, LLC. | $18.02 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802918601 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.79 | 02/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763326036 | CMS |
| GlaxoSmithKline, LLC. | $9.63 | 02/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803170163 | CMS |
| Octapharma USA, Inc. | $14.76 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812974635 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $31.71 | 02/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820007239 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.93 | 01/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820007237 | CMS |
| GlaxoSmithKline, LLC. | $12.43 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802576713 | CMS |
| PFIZER INC. | $20.51 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833281059 | CMS |
| GENZYME CORPORATION | $21.58 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843452909 | CMS |
| AstraZeneca Pharmaceuticals LP | $68.00 | 01/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834339857 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.63 | 01/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834351337 | CMS |
| GlaxoSmithKline, LLC. | $11.90 | 01/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803118653 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $234,496.60 | 338 |
| PY2024 | Principal investigator | $198,958.61 | 314 |
| PY2023 | Principal investigator | $263,371.10 | 129 |
| PY2022 | Principal investigator | $225,959.04 | 35 |
| PY2021 | Principal investigator | $240,737.24 | 40 |
| PY2020 | Principal investigator | $224,016.09 | 41 |
| PY2019 | Principal investigator | $291,477.30 | 51 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
338 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $383.00 | 12/24/2025 | Non-covered Recipient Entity Adac Research PA | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226138784 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $319.00 | 12/24/2025 | Non-covered Recipient Entity Adac Research PA | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable | No dispute reported | 06/30/2026 | 1226138789 |
| Principal investigator 1 | GENZYME CORPORATION | $13,608.42 | 12/22/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138781 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $573.75 | 11/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184256987 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $573.75 | 11/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184256989 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $573.75 | 11/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184256991 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $573.75 | 11/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184256993 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251570 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251572 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251574 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251576 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251578 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251590 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251602 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251620 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251622 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251624 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251626 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251628 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251630 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251632 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184251634 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252284 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252286 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252288 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252290 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252292 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252294 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252296 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252298 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252300 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252302 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252304 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252306 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252308 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252310 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252312 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252314 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252316 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252318 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252332 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252352 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252370 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252388 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252408 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252424 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252426 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252428 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252430 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252432 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252434 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252436 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 10/22/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184252438 |
| Principal investigator 1 | GENZYME CORPORATION | $10,656.96 | 10/20/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138769 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 09/10/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184235795 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 09/10/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184235797 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/10/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184235799 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 09/10/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184235801 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 09/10/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184235803 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/10/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184235805 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 09/10/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184235807 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 09/10/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184235809 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/10/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184235811 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 09/10/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184235813 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184233878 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184233880 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184233882 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,125.95 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234249 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234251 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234253 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234297 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234389 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234391 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234393 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234395 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $64.80 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234401 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234519 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $472.50 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234591 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234637 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234683 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234685 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234709 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234711 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234713 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234715 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234737 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234739 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234747 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234855 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234895 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234901 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234913 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $708.75 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $270.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234923 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234925 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,460.75 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234929 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234931 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234933 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234935 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234937 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234939 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234941 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234943 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234945 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234947 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234949 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $70.20 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234951 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234953 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234955 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234957 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $583.25 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234959 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234961 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234963 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234965 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,417.50 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234967 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $70.20 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234969 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234971 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234973 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234975 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234977 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 09/03/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184234987 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 08/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569706 |
| Principal investigator 1 | Genentech, Inc. | $9,660.00 | 08/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569710 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 08/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569713 |
| Principal investigator 1 | Genentech, Inc. | $2,221.00 | 08/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569717 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 08/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569720 |
| Principal investigator 1 | GENZYME CORPORATION | $2,412.32 | 08/04/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138758 |
| Principal investigator 1 | GENZYME CORPORATION | $1,906.24 | 08/04/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138761 |
| Principal investigator 1 | AstraZeneca UK Limited | $191.14 | 07/09/2025 | Non-covered Recipient Entity ALLERGIC DISEASE AND ASTHMA CENTER, PA | BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist | No dispute reported | 06/30/2026 | 1185539753 |
| Principal investigator 1 | AstraZeneca UK Limited | $13,075.00 | 07/02/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist | No dispute reported | 06/30/2026 | 1185539747 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $215.16 | 06/30/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184212045 |
| Principal investigator 1 | GENZYME CORPORATION | $10,716.96 | 06/16/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138755 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $50,151.10 | 06/15/2025 | Non-covered Recipient Entity ALLERGIC DISEASE AND ASTHMA CENTER | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190306449 |
| Principal investigator 1 | GENZYME CORPORATION | $540.00 | 05/27/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138750 |
| Principal investigator 1 | Genentech, Inc. | $476.00 | 05/14/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569628 |
| Principal investigator 1 | Genentech, Inc. | $1,011.00 | 05/14/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569633 |
| Principal investigator 1 | Genentech, Inc. | $801.00 | 05/14/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569702 |
| Principal investigator 1 | GENZYME CORPORATION | $1,448.48 | 05/12/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138746 |
| Principal investigator 1 | Genentech, Inc. | $2,768.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569636 |
| Principal investigator 1 | Genentech, Inc. | $5.46 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569641 |
| Principal investigator 1 | Genentech, Inc. | $1,300.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569645 |
| Principal investigator 1 | Genentech, Inc. | $1,011.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569649 |
| Principal investigator 1 | Genentech, Inc. | $19.34 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569653 |
| Principal investigator 1 | Genentech, Inc. | $57.14 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569656 |
| Principal investigator 1 | Genentech, Inc. | $51.36 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569659 |
| Principal investigator 1 | Genentech, Inc. | $90.03 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569668 |
| Principal investigator 1 | Genentech, Inc. | $1,200.15 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569673 |
| Principal investigator 1 | Genentech, Inc. | $5,283.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569677 |
| Principal investigator 1 | Genentech, Inc. | $681.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569681 |
| Principal investigator 1 | Genentech, Inc. | $275.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569686 |
| Principal investigator 1 | Genentech, Inc. | $579.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569690 |
| Principal investigator 1 | Genentech, Inc. | $50.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569693 |
| Principal investigator 1 | Genentech, Inc. | $497.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569698 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $70.20 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192803 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192843 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192853 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192871 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192883 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192931 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192963 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192969 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184192999 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184193147 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184193189 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184193231 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184193291 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 05/07/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184193299 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,509.00 | 05/05/2025 | Non-covered Recipient Entity Adac Research PA | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226138735 |
| Principal investigator 1 | GENZYME CORPORATION | $1,700.00 | 04/28/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138741 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $573.75 | 04/23/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184186247 |
| Principal investigator 1 | Genentech, Inc. | $131.00 | 04/02/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough | No dispute reported | 06/30/2026 | 1211569664 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,020.88 | 03/28/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185539751 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $383.00 | 03/24/2025 | Non-covered Recipient Entity Adac Research PA | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226138738 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174636 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174638 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $270.00 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174640 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $270.00 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174642 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $270.00 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174644 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174646 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174648 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174650 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174652 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174654 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174656 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174658 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174660 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174662 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174664 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174666 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174668 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174670 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174672 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174674 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174676 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174678 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174680 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174682 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174684 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174686 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $270.00 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174688 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174690 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174692 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/19/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184174694 |
| Principal investigator 1 | GENZYME CORPORATION | $3,277.12 | 03/17/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138722 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157261 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157263 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157265 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157267 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157269 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157275 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157277 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157279 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $604.80 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157281 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157283 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157285 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157287 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157289 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157291 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157293 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157295 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157297 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157299 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157301 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157303 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157305 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157307 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157309 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157311 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157313 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157315 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157317 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157319 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157321 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157323 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157325 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157327 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157331 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157333 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157335 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157337 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157339 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157341 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157343 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157345 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157347 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157349 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157351 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157353 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157355 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157357 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157359 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157361 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157363 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $70.20 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157365 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.45 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157367 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157369 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $708.75 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157371 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.45 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157373 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.45 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157375 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.45 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157377 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $472.50 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157379 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.45 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157381 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $708.75 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157383 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.45 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157385 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157387 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157389 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $472.50 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157391 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.45 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157393 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157395 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157397 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.45 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157399 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157401 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157403 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157405 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157407 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157409 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157411 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157413 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157415 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157417 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157419 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157421 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157423 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157425 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157427 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157431 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157433 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157435 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157437 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157439 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157441 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157443 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157445 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157447 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.70 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157449 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157451 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157453 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157455 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157461 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33.75 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157467 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $35.10 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157471 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $27.00 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157473 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.65 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157475 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157477 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $39.15 | 03/06/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184157479 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,600.00 | 03/04/2025 | Non-covered Recipient Entity Adac Research PA | ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig | No dispute reported | 06/30/2026 | 1226138717 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $573.75 | 02/27/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184156020 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $10,066.36 | 02/24/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod | No dispute reported | 06/30/2026 | 1185539745 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,240.09 | 02/24/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States | No dispute reported | 06/30/2026 | 1185539749 |
| Principal investigator 1 | GENZYME CORPORATION | $360.00 | 02/18/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138725 |
| Principal investigator 1 | GENZYME CORPORATION | $3,477.28 | 02/18/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138728 |
| Principal investigator 1 | GENZYME CORPORATION | $1,350.00 | 02/18/2025 | Non-covered Recipient Entity Adac Research PA | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226138731 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $215.16 | 02/05/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184152101 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $573.75 | 01/02/2025 | Non-covered Recipient Entity ADAC RESEARCH PA | ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | No dispute reported | 06/30/2026 | 1184144686 |